Nu­va­tion inks all-stock deal for US-Chi­na on­col­o­gy biotech An­Heart

Nu­va­tion Bio plans to buy An­Heart Ther­a­peu­tics in an all-stock deal, the can­cer drug de­vel­op­ers said Mon­day morn­ing, in a move that could turn Nu­va­tion in­to a com­mer­cial drug­mak­er next year.

Cur­rent An­Heart share­hold­ers will own about 33% of the com­bined Nu­va­tion as part of the deal, which is an­tic­i­pat­ed to close in the sec­ond quar­ter, the com­pa­nies said.

An­Heart, a US and Chi­na biotech, was like­ly in need of cash. The biotech last dis­closed a $61 mil­lion Se­ries B in De­cem­ber 2021, and that round was ex­pect­ed to last the biotech on­ly 12 to 18 months, co-founder and then-busi­ness chief Li­hua Zheng told End­points News at the time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER